IVD Market Top 25 Companies presents advancements in in vitro diagnostics (IVD) by the Top 25 firms in the industry and provides an overview of the most recent trends and developments. Companies included are:
The report examines the major manufacturers in the IVD industry in terms of
- Recent Revenue History and Commentary
- Business Overview
- Revenue in Selected Test Segments
- Current and New Products
- Competitive Activity: M&A, Partnerships and Other Moves
In addition to the in-depth company information, the report examines market trends, including those involving gene editing, liquid biopsy, microbiome, patient service center revival, partnering and acquisitions, direct to consumer genomics, and growing IVD company activity in Asia, Africa, and Latin America.
IVD Market Top 25 Companies also presents highlights of IVD industry developments as demonstrated by a selection of small and niche firms in 2016 and the first half of 2017, which are preparing for the future with the development of next generation systems, informatics to help labs manage and retrieve test data, new infectious disease diagnostics, and gene-based oncology tests for targeted therapeutics.
This report on the advancements in in vitro diagnostics at the hands of the major companies provides an overview of the most recent trends and developments in the industry. It is not a comprehensive review of the diagnostics industry in general.
Clinical laboratory technology has changed dramatically in the past few years, due to the publication of the human genome project and advances in functional genomics, bioinformatics, miniaturization and microelectronics. Not five years ago it would have been almost inconceivable to see research technologies such as genome sequencing and mass spectroscopy play a pivotal role in improving lab medicine. Their influence is felt in personalized medicine, inherited diseases, pathogen detection, antibiotic resistance testing, blood banking and much more to come.
The top five majors continue to bring innovations to clinical diagnostics. However, of particular interest in the past year or so are the efforts made by companies such as Bio-Rad Laboratories, Illumina and Thermo Fisher Scientific. These and other companies are translating their portfolio of research-based molecular solution to clinical tools.
A review of the advancements reported by the major IVD companies included in this report shows innovations in CRISPR gene editing that is being adapted to the diagnosis of problematic diseases and the development of new therapeutics.